By Amira McKee

Apimeds Pharmaceuticals is set to discuss a treatment for osteoarthritis using bee venom at a Type C meeting with the Food and Drug Administration.

The pharmaceutical company, along with L kahi Therapeutics, said Wednesday that the meeting will be held May 4, and represents an important step in its U.S. regulatory strategy for the treatment, LT-100.

LT-100 is pure honeybee venom originally developed and approved in South Korea, the companies said. Apimeds and L kahi plan to advance the program in the U.S. by integrating historical data with development standards.

"LT-100 has broad therapeutic potential, and we believe that updating the route of administration to reflect current clinical best practices, while reducing burden for patients and providers, positions the program well for continued progress," President of Apimeds and Chief Executive Officer of L kahi Therapeutics Erik Emerson said.

Write to Amira McKee at amira.mckee@wsj.com

(END) Dow Jones Newswires

February 11, 2026 17:48 ET (22:48 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.